최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Biomaterials, v.247, 2020년, pp.119960 -
Ahn, Young Ha (Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) , Ren, Long (SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, and School of Chemical Engineering, Sungkyunkwan University) , Kim, Seok Min (Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) , Seo, Sang-Hwan (Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) , Jung, Cho-Rok (Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) , Kim, Da Seul (Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) , Noh, Ji-Yoon (Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and B) , Lee, Soo Yun , Lee, Hyunseung , Cho, Mi Young , Jung, Haiyoung , Yoon, Suk Ran , Kim, Jung-Eun , Lee, Sang Nam , Kim, Sohyun , Shin, Il Woo , Shin, Hong Sik , Hong, Kwan Soo , Lim, Yong Taik , Choi, Inpyo , Kim, Tae-Don
Abstract Adoptive transfer of natural killer (NK) cells is becoming one of the most important parts of cancer immunotherapy. However, recent accomplishments have focused on the improvement of the targeting effects based on the engineering of chimeric antigen receptors (CARs) on cell surfaces. Despi...
Nature Mellman 480 480 2011 10.1038/nature10673 Cancer immunotherapy comes of age
Nat. Rev. Canc. Pardoll 12 252 2012 10.1038/nrc3239 The blockade of immune checkpoints in cancer immunotherapy
Nat. Rev. Canc. Rosenberg 8 299 2008 10.1038/nrc2355 Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Nat. Med. Rosenberg 10 909 2004 10.1038/nm1100 Cancer immunotherapy: moving beyond current vaccines
Curr. Pharmaceut. Biotechnol. Androulla 19 5 2018 10.2174/1389201019666180418095526 CAR T-cell therapy: a new era in cancer immunotherapy
N. Engl. J. Med. Rosenbaum 377 1313 2017 10.1056/NEJMp1711886 Tragedy, perseverance, and chance - the story of CAR-T therapy
Nat. Rev. Clin. Oncol. Brudno 15 31 2017 10.1038/nrclinonc.2017.128 Chimeric antigen receptor T-cell therapies for lymphoma
Nat. Rev. Clin. Oncol. Jackson 13 370 2016 10.1038/nrclinonc.2016.36 Driving CAR T-cells forward
NK Cells in Therapy of Cancer Bachanova 19 133 2014
Nat. Rev. Immunol. Chiossone 18 671 2018 10.1038/s41577-018-0061-z Natural killer cells and other innate lymphoid cells in cancer
Immunol. Rev. Moretta 224 58 2008 10.1111/j.1600-065X.2008.00651.x Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias
Nat. Rev. Immunol. O'Brien 19 282 2019 10.1038/s41577-019-0139-2 Immunometabolism and natural killer cell responses
Cell. Mol. Immunol. Habif 16 415 2019 10.1038/s41423-019-0224-2 Targeting natural killer cells in solid tumors
Canc. Discov. Melero 4 522 2014 10.1158/2159-8290.CD-13-0985 T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy
Front Oncol Nayyar 9 51 2019 10.3389/fonc.2019.00051 Overcoming resistance to natural killer cell based immunotherapies for solid tumors
Frontiers in Oncology Koehl 3 2013 10.3389/fonc.2013.00118 Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol
OncoImmunology Koehl 5 e1115178 2016 10.1080/2162402X.2015.1115178 Advances in clinical NK cell studies: donor selection, manufacturing and quality control
Hum. Gene Ther. Stephan 28 897 2017 10.1089/hum.2017.157 Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-cd123-CAR-expressing effector cells
Acta Pharmacol. Sin. Hu 39 167 2017 10.1038/aps.2017.125 Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Leukemia Liu 32 520 2017 10.1038/leu.2017.226 Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
Haycock 1 2011 3D Cell Culture: Methods and Protocols 3D cell culture: a review of current approaches and techniques
Tissue Eng. B Rev. Fan 23 451 2017 10.1089/ten.teb.2016.0465 Macroporous hydrogel scaffolds for three-dimensional cell culture and tissue engineering
Sci. Rep. Kim 7 40623 2017 10.1038/srep40623 Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster
Br. J. Ophthalmol. Gomes 88 821 2004 10.1136/bjo.2003.027573 Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro
Investig. Ophthalmol. Vis. Sci. Inoue 34 2313 1993 The effect of hyaluronic acid on corneal epithelial cell proliferation
Adv. Funct. Mater. Ren 28 1804490 2018 10.1002/adfm.201804490 Degradation-regulatable Architectured implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy
Sci. Rep. Kim 7 40623 2017 10.1038/srep40623 Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster
Sci. Rep. Kim 4 7157 2014 10.1038/srep07157 Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells
Mol. Canc. Ertel 5 55 2006 10.1186/1476-4598-5-55 Pathway-specific differences between tumor cell lines and normal and tumor tissue cells
Cancer Epidemiology Liu 37 930 2013 10.1016/j.canep.2013.08.011 Genetic variations in CTLA-4, TNF-α, and LTA and susceptibility to T-cell lymphoma in a Chinese population
J. Immunol. Luger 143 1206 1989 10.4049/jimmunol.143.4.1206 IFN-beta 2/IL-6 augments the activity of human natural killer cells
J. Neuro Oncol. Whiteway 111 113 2013 10.1007/s11060-012-1000-7 Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells
Nat. Immunol. Bezman 13 1000 2012 10.1038/ni.2395 Molecular definition of the identity and activation of natural killer cells
J. Thorac. Dis. Su 6 949 2014 Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma
Transl. Lung Cancer Res. Uramoto 3 242 2014 Recurrence after surgery in patients with NSCLC
Nat. Rev. Mater. Dellacherie 4 379 2019 10.1038/s41578-019-0106-3 Macroscale biomaterials strategies for local immunomodulation
Canc. Res. Liu 75 3596 2015 10.1158/0008-5472.CAN-15-0159 Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice
Cancer Control Rocha-Lima 14 295 2007 10.1177/107327480701400313 EGFR targeting of solid tumors
Immunol. Cell Biol. Yong 95 356 2017 10.1038/icb.2016.128 CAR T-cell therapy of solid tumors
Curr. Opin. Immunol. Chen 51 103 2018 10.1016/j.coi.2018.03.002 Driving CARs on the uneven road of antigen heterogeneity in solid tumors
Immunotherapy Geller 3 1445 2011 10.2217/imt.11.131 Use of allogeneic NK cells for cancer immunotherapy
Front. Immunol. Gras Navarro 6 2015 10.3389/fimmu.2015.00202 Therapeutic potential and challenges of natural killer cells in treatment of solid tumors
Immunotherapy Iliopoulou 59 1781 2010 A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer, Cancer Immunology
J. Innate Immunity Stojanovic 3 355 2011 10.1159/000325465 Natural killer cells and solid tumors
Childs 234 2013 Bringing Natural Killer Cells to the Clinic: Ex Vivo Manipulation
Cytotherapy Lapteva 14 1131 2012 10.3109/14653249.2012.700767 Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.